Drug intelligence / Profile preview

coenzyme q10 + trastuzumab

Development stage: Unknown
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy where coenzyme Q10 (CoQ10) is administered alongside trastuzumab to reduce cardiotoxicity in HER2-positive breast cancer patients. CoQ10 provides cardioprotection by increasing ejection fraction and decreasing inflammatory biomarkers and cardiac enzyme levels, allowing patients to continue beneficial trastuzumab therapy with reduced cardiac side effects.

Other names: ubiquinone + trastuzumab

Targets

Mitochondrial electron transport chain complexes and cellular lipid membranes

Beyond the preview

Go deeper on coenzyme q10 + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coenzyme q10 + trastuzumab.

Explore the full profile